The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by STOROSUM, J. G.
* Articles by BROEKMANS, A. W.
* Search for Related Content
PubMed
* Articles by STOROSUM, J. G.
* Articles by BROEKMANS, A. W.
Related Collections
* Depression
* Miscellaneous Ethics
* Suicide
* Antidepressants
Am J Psychiatry 159:681, April 2002
© 2002 American Psychiatric Association


Letter to the Editor

Dr. Storosum and Colleagues Reply

JITSCHAK G. STOROSUM, M.D., BARBARA J. VAN ZWIETEN, PH.D., WIM VAN DEN BRINK, M.D., PH.D., BERTHOLD P.R. GERSONS, M.D., PH.D., and ANDRÉ W. BROEKMANS, M.D., PH.D.
Amsterdam, the Netherlands

To the Editor: We agree with Dr. Goldney that it might be possible to read a difference between the conclusion in the abstract and the text concerning the exclusion of patients at risk for suicide. However, almost all short-term placebo-controlled studies of major depression are conducted by excluding patients with "suicide risk." Therefore, in practice, placebo-controlled short-term studies are conducted in a patient population in which patients with "suicide risk" are excluded.

With regard to long-term studies, in the placebo-controlled phase of withdrawal studies and the extension phase of extension studies, only responders or remitters are included (1). Therefore, the patients included in the placebo-controlled phase of withdrawal studies and the extension phase of extension studies are probably not at risk for suicide.

On the basis of our study results, including trials conducted in the United States and in the European Union, we are convinced that the conclusion in the abstract reflects the substance of the text and that fear of increased risk of (attempted) suicide in placebo groups should not be an argument against performing short-term and long-term placebo-controlled trials in studies of major depression.

Reference

  1. Storosum JG, van Zwieten BJ, Vermeulen HD, Wohlfarth T, van den Brink W: Relapse and recurrence prevention in major depression: a critical review of placebo-controlled efficacy studies with special emphasis on methodological issues. Eur Psychiatry 2001; 16:327-335




This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
Services
* Email this article to a Colleague
* Similar articles in this journal
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via Google Scholar
Google Scholar
* Articles by STOROSUM, J. G.
* Articles by BROEKMANS, A. W.
* Search for Related Content
PubMed
* Articles by STOROSUM, J. G.
* Articles by BROEKMANS, A. W.
Related Collections
* Depression
* Miscellaneous Ethics
* Suicide
* Antidepressants


Get information about faster international access.

Privacy Policy

Copyright © 2002 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org